Experience with amoxycillin/sulbactam (trifamox IBL) in the treatment of frequently ill children

Antibiotiki i Khimioterapiya

Volumn 53, Issue 5-6, 2008, Pages 35-41

  Savenkova, M S ^a   Afanasyeva, A A ^a   Neizhko, L Yu ^a   Abdulaev, A K ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; SULBACTAM; TRIFAMOX IBL;

ARTICLE; CHILD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; FEVER; HUMAN; LYMPHATIC SYSTEM DISEASE; MALE; PATHOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; FEVER; HUMANS; LYMPHATIC DISEASES; MALE; RESPIRATORY TRACT INFECTIONS; SULBACTAM; TREATMENT OUTCOME;

EID: 56549112853     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Consilium medicum 2007; 2: 30-35.
2. Russian source
3. Russian source
4. Kozlov R. S., Sivaja O. V., Strachounski L. S. 7-Year monitoring of resistance of clinical S.pneumoniae in Russia: results of prospective multicenter study (PEGASonus). Proceedings of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2005; sep 21-24: New Orlean.
5. Russian source
6. Russian source
7. Russian source
8. Jacobs M., Felmingham D., Appelbaum P. et al. The Alexander Project 1998-2000; susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 2: 229-246.
9. Sher L., Arguedas A., Husseman M. et al. Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. Pediatr Infect Dis J 2005; 24: 4: 301-308.
10. Sethi S., Breton J., Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin/clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 2005; 49: 1: 153-160.
11. Russian source
12. Clavero C. A. Acute otitis media, efficacy and tolerability of amoxicillin/silbactam combination. La pensa Médica Argentina, 1990; 77: 20-23.
13. Russian source